Building a biotechnology company? Check this Indication Checklist
Trends in Biotechnology · 2026-08
DOI: 10.1016/j.tibtech.2026.07.033 ↗Kurz gefasst
Fachartikel in der Zeitschrift Trends in Biotechnology, 2026-08. Verfasst von William N Hait. Beteiligte Einrichtung: Bill Hait Biomedical Innovations LLC, 13471 Le Havre Dr, Palm Beach Gardens, FL 33410, USA. Electronic address: Williamhait49@gmail.com. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Biotechnology companies must carefully consider the choice of the first disease indication for their new drug. There are several key elements that can help guide this critical decision. Drawing on years of experience, this article provides an 'Indication Checklist' with recommendations designed to help.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Bill Hait Biomedical Innovations LLC, 13471 Le Havre Dr, Palm Beach Gardens, FL 33410, USA. Electronic address: Williamhait49@gmail.com.
Zitieren
APA
Hait, W. N. (2026). Building a biotechnology company? Check this Indication Checklist. Trends in Biotechnology. https://doi.org/10.1016/j.tibtech.2026.07.033
Vancouver
Hait WN. Building a biotechnology company? Check this Indication Checklist. Trends in Biotechnology. 2026. doi:10.1016/j.tibtech.2026.07.033
BibTeX
@article{Hait2026,
author = {Hait, William N},
title = {Building a biotechnology company? Check this Indication Checklist},
journal = {Trends in Biotechnology},
year = {2026},
doi = {10.1016/j.tibtech.2026.07.033}
}
EUVIMED